OS Therapies Incorporated (OSTX)
NYSEAMERICAN: OSTX · Real-Time Price · USD
1.920
+0.100 (5.49%)
Dec 5, 2025, 4:00 PM EST - Market closed
OS Therapies Employees
As of December 31, 2024, OS Therapies had 5 total employees, including 4 full-time and 1 part-time employees. The number of employees increased by 1 or 25.00% compared to the previous year.
Employees
5
Change
1
Growth
25.00%
Revenue / Employee
n/a
Profits / Employee
-$4,051,244
Market Cap
67.61M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 5 | 1 | 25.00% |
| Dec 31, 2022 | 4 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
OSTX News
- 1 day ago - OS Therapies Announces FDA PDUFA Waiver & EMA Grants Union Marketing Authorisation Eligibility - Newsfile Corp
- 11 days ago - OS Therapies Receives Non-Proprietary Name 'daznelimgene lisbac' for OST-HER2 from World Health Organization - Newsfile Corp
- 15 days ago - Stonegate Capital Partners Updates Coverage on OS Therapies Inc. (OSTX) 3Q25 - Newsfile Corp
- 16 days ago - OS Therapies to Spinoff OS Animal Health into Standalone Public Company - Newsfile Corp
- 19 days ago - OS Therapies Reports Third Quarter 2025 Financial Results and Provides Business Update - Newsfile Corp
- 6 weeks ago - OS Therapies Announces Overall and Event Free Survival Key Subgroup Data for OST-HER2 in Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma - Newsfile Corp
- 7 weeks ago - OS Therapies Granted Final Type C Meeting by U.S. FDA and pre-MAA Meeting by U.K. MHRA for OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma - Newsfile Corp
- 2 months ago - OS Therapies Announces Statistically Significant Positive Final 2-Year Overall Survival Data from Phase 2b Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully-Resected, Pulmonary Metastatic Osteosarcoma - Newsfile Corp